eisai integrated report 2020

Eisai Co., Ltd. Eisai revenue for the twelve months ending June 30, 2022 was $4.769B, a 11.07% decline year-over-year. Read our factsheet. How Eisai is utilizing digital workspace innovations in a post-pandemic era. Glassdoor users rated their interview experience at Eisai as 72.0% positive with a difficulty rating score of 2.86 out of 5 (where 5 is the highest level of difficulty). Published. 405-2. Eisai's Commitment to Scientific Evidence and Patient Safety. DEP encourages the public to provide constructive comments during this period. Introduction Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. Note: Responsibility for the content of participants" public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact. 2018. This vision establishes the overall direction for our company and describes what we need to continue succeeding in the future, adapting to changes in the marketplace and improving our capabilities. View key facts. CEO Christian Klein shares his thoughts in a letter to shareholders. Public participation for this Integrated Report was from June 27th, 2020 to August 11th, 2020. eisai integrated report 2020. Metrics. Eisai files for approval of Alzheimer's . IR DayQ&A Session about 2020 MediumTerm Business Plan[June 19, 2018] . The Group recorded 34.5 billion (20.7 billion in the same period of the previous fiscal year) as sales milestone . EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 StudyFirst Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPANIf approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimers diseaseAducanumab is now under regulatory review in Japan, Europe and the United States, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIESThis collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of-synuclein misfolding and aggregation, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING, AbbVie and Eisai Announce an approval for additional indication of HUMIRA, a fully Human Anti-TNF Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASEWITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS, EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPANA once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies, EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA FOR USE IN PEDIATRIC PATIENTS, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaLENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibResults of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at Upcoming Medical Meeting, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using BloodThe Content Presented at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference, Update on FDA Advisory Committees meeting on aducanumab in Alzheimers disease, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's DiseaseIf approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimers disease and to meaningfully change the course of Alzheimers disease, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE 13TH CLINICAL TRIALS ON ALZHEIMERS DISEASE CONFERENCE, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORMAiming to make a new contribution through a One-Stop Online Service for people living with Dementia in China, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIALAMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19AMGENS APREMILAST AND EISAIS ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK, Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies, NOTICE REGARDING BIOGENS DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMERS DISEASE, SUPPLEMENTARY NEW DRUG APPLICATIONS FOR ANTI-EPILEPTIC DRUG FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES ACCEPTED IN CHINA, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGYEstablishment of Social Cooperation Program Protein Degradation Drug Discovery, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCEAdopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)", Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITISFilgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials, EISAI RECEIVES POSITIVE OPINION FROM EMAS CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA IN PEDIATRIC PATIENTS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy, EISAI PRESENTS LATEST DATA OF PHASE I CLINICAL TRIAL ON LIPOSOMAL FORMULATION OF ANTI-CANCER AGENT HALAVEN (ERIBULIN) AT ESMO VIRTUAL CONGRESS 2020, EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN VIETNAM, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2020, EISAI TO TAKE OVER MANUFACTURING AND MARKETING APPROVAL FOR EQUFINA 50MG TABLETS (SAFINAMIDE MESILATE) IN JAPAN FROM MEIJI SEIKA PHARMA, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care productsEISAI TO LAUNCH SAHNE MEDICAL SPRAY AND SAHNE MEDICAL CREAMSahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid, EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 34th ANNUAL SLEEP MEETING (SLEEP2020), FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewPriority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimers disease, EISAI SUPPORTS RELIEF EFFORTS FOR THE HEAVY RAIN EVENT OF JULY 2020 IN JAPAN, APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENTEISAI DEMENTIA PLATFORM EASIIT COMMENCES, EISAI LISTED FOR 19TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2020, Smartphone app for vital signs measurement of patients with the novel coronavirus infection Experimental study project adopted as AMED projectPreventing medical infrastructure collapse by a monitoring system linked to LINE, INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMERS DISEASE, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDEDRESEARCH ACTIVITIES COMMENCE, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers DiseaseIf approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimers disease, Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TAZEMETOSTAT FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONGFIRST NEW DRUG APPLICATION FOR DAYVIGO IN ASIA OUTSIDE JAPAN, EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN, NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA LAUNCHED IN JAPAN, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVIDGCAR, EISAI AND UPMC, ON BEHALF OF REMAP-CAP INVESTIGATOR NETWORK, ANNOUNCE ERITORANS INCLUSION IN REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS WITH MODERATE AND SEVERE COVID INFECTIONEISAIS ERITORAN SELECTED AS THE FIRST INVESTIGATIONAL IMMUNE MODULATION THERAPY TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, EISAI RECEIVES APPROVAL FOR PARKINSONS DISEASE TREATMENT EQUFINA IN SOUTH KOREA, SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS, CONTINUATION OF POLICY FOR PROTECTION OF THE COMPANYS CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN), EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICASUPPORT FOR CONTINUATION OF ELIMINATION ACTIVITIES FOR NEGLECTED TROPICAL DISEASES AND SUPPORT FOR DEVELOPMENT AND POPULARIZATION OF MOBILE HEALTH PLATFORM, BRAIN PERFORMANCE (BRAIN-HEALTH) SELF-CHECK TOOL NOUKNOW TO BE USED IN BEAUTY SALONS, EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA, AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA, a Fully Human Anti-TNF Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa, Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting, The effect of SEI-I* evokes the joy of eatingEISAI TO LAUNCH NEW SELBELLE PREMIUM TABLETS AND NEW SELBELLE PREMIUM FINE GRANULESThe first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes, EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING, EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN THE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING) BY INSTITUTIONAL INVESTOR MAGAZINE, Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA, DISCOVERY RESEARCH ON MULTIKINASE INHIBITOR LENVATINIB HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 20, EISAI TO LAUNCH DIGITAL TOOL NOUKNOW IN JAPAN FOR REGULAR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), All-case Surveillance Condition for Approval of Actonel 17.5 mg tablets for Treatment of Pagets Disease of Bone Cleared in Japan, Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDSFOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA, EISAI TO SUPPORT COUNTER MEASURES FOR CHINAS NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA, EISAI COMMENCES JOINT RESEARCH AND DEVELOPMENT OF CANCER GENE PANEL TEST WITH PERSONAL GENOME DIAGNOSTICS INC. Explore. EBARA Group at a Glance. This website uses cookies to enhance your browsing experience. Integrated Report 2020. Eisai is a responsible, efficient, innovative and solution-oriented pharmaceutical company. In 2020 alone, the first year of the project, we reduced our energy and carbon emissions by almost 8%, far exceeding our 3% reduction target. Candidates interviewing for Senior SAS Programmer and Oncology Sales Specialist rated their interviews as the hardest, whereas interviews for Principal Researcher and Quality . All pages (A3-sized) All pages (A4-sized) Cover. Annual Report 2020 (year ended December 31) Annual Report 2020. 2019. About Eisai "Corporate Governance Report Notice" November 30, 2022 January 10, 2020. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. Eisai annual revenue for 2021 was $6.072B, a 5.12% decline from 2020. 2017. Through knowledge exchange, collaboration, and engagement, HKLSS aims to attract, cultivate, and retain talent in Hong Kong's life sciences and biotechnology sectors. WOODCLIFF LAKE, N.J., Nov. 2, 2020 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and research from the company's Alzheimer's disease (AD) pipeline, including BAN2401, anti-microtubule binding region (MTBR) tau antibody E2814 and lemborexant. This offers the ability to convey tremendous amounts of information in a way that is much easier to understand. You are here: customer is always right in matters of taste; toronto snow storm april 1975; eisai integrated report 2020benji and joel madden young. 2020 Integrated Report 7.7 MB. 2017 Integrated Report 8.2 MB. OUR PIPELINE REPRESENTS HOPE FOR PATIENTS, THEIR FAMILIES AND CAREGIVERS. Initiatives for Improving Access to Medicines. eisai integrated report 2020. Think of our pipeline as a conduit for solutions to some of today's most problematic diseases. Online sales and delivery automation capacity. Initiatives for Improving Access to Medicines. In its 10th year, the Drugs to Watch report provides in-depth predictive analysis of drugs with the potential to transform treatment paradigms and serve unmet patient needs. Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIME, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023, Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimers Disease, EISAIS APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMERS DISEASE, SETS FORTH OUR CONCEPT OF SOCIETAL VALUE OF MEDICINE IN RELATION TO PRICE OF MEDICINE, FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimers Disease, To Develop Japans First Blood Biomarker-Based Diagnostic Workflow for Dementia, EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN, Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange, RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMERS DAY, SEPTEMBER 21, Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma, Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022, Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022, EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP KIGALI DECLARATION FOR ELIMINATING NEGLECTED TROPICAL DISEASES, EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL, EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETING, EISAI CONTRIBUTES TO THE SCIENCE OF CANCER MEDICINE AT ASCO 2022, Announcement about an approval for additional indication of Jyseleca, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapies, Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimers Disease, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma, EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTED TROPICAL DISEASES, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIME, FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAIS ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU. By using this site, you agree to our use of cookies. Eisai Rated "A", the highest rating in the CDP Climate Change Report 2019. 2023 Release; 405-1. The targets are that by 2030, 80% of people living with diabetes mellitus are diagnosed, and that 80% . We acknowledge that it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues. It was listed on the Tokyo/Osaka stock exchange in 1961 and began its global operations soon after. The corporate landscape is changing and Integrated Reporting is an ideal tool with which to explore value creation. The report serves as a key . Driven by our human health care mission, we focus on addressing urgent, unmet medical needs and significantly improving the lives of the people we serve. Integrated Reportsformerly Annual Reports 2020. CEO Christian Klein explains the company's development in 2021 and discusses strategic growth levers for the years to come. 8 Altmetric. Owned . FY 2020 Q3 Quarterly Average Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 . We are committed to transparency and disclosure, and our Integrated Report 2020 shows the progress we are making toward a world without cigarettes. Integrated Report 2022 PDF | 13,173 KB. Annual Integrated Report. On top of this, the entire driving range is motor-powered. This website uses cookies to enhance your browsing experience. SDG 1: End poverty in all its forms everywhere, SDG 2: End hunger, achieve food security and improved nutrition and promote sustainable agriculture, SDG 3: Ensure healthy lives and promote well-being for all at all ages, SDG 4: Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all, SDG 5: Achieve gender equality and empower all women and girls, SDG 6: Ensure availability and sustainable management of water and sanitation for all, SDG 7: Ensure access to affordable, reliable, sustainable and modern energy for all, SDG 8: Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all, SDG 9: Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation, SDG 10: Reduce inequality within and among countries, SDG 11: Make cities and human settlements inclusive, safe, resilient and sustainable, SDG 12: Ensure sustainable consumption and production patterns, SDG 13: Take urgent action to combat climate change and its impacts, SDG 14: Conserve and sustainably use the oceans, seas and marine resources for sustainable development, SDG 15: Protect, restore and promote sustainable use of terrestrial ecosystems, sustainably manage forests, combat desertification, and halt and reverse land degradation and halt biodiversity loss, SDG 16: Promote peaceful and inclusive societies for sustainable development, provide access to justice for all and build effective, accountable and inclusive institutions at all levels, SDG 17: Strengthen the means of implementation and revitalize the global partnership for sustainable development, Opportunities and responsibilities that one or more SDGs represent to our business, Where the companys priorities lie with respect to one or more SDGs, Goals and indicators set by our company with respect to one or more SDGs, How one or more SDGs are integrated into the companys business model, The (expected) outcomes and impact of your companys activities related to the SDGs, If the companies' activities related totheSDGs are undertaken in collaboration with other stakeholders, Other established or emerging best practices. The 2020 Integrated Report continues the new digital and fully interactive format created in 2018. Use a + to require a term in results and - to exclude terms. This direction of travel - which is voluntary - is focused on driving more authentic, comprehensive and meaningful information about all aspects of an organisation's performance and value creation story delivering benefits for both internal and external stakeholders. Ltd. ("the Company") discloses its consolidated financial statements in accordance with the International Financial Reporting Standards (IFRS). We've been breaking through ever since, with solutions and therapies that help improve the lives of the people we serve. Example: +water -Europe Read more, Our Response to the Novel Coronavirus Infection, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Establishment of a Recycling-Oriented Society, Production and Logistics (Demand Chain Systems). [Select all that apply], With respect to your companys actions to advance the Sustainable Development Goals (SDGs), the COP describes: [Select all that apply]. To enhance your browsing experience an ideal tool with which to explore value creation June 30 2022... Discusses strategic growth levers for the twelve months ending June 30, 2022 was 6.072B. Company & # x27 ; s development in 2021 and discusses strategic growth levers for the years to come 30! Of today & # x27 ; s medicines and over-the-counter products annual revenue the! Of today & # x27 ; s is motor-powered a Session about 2020 MediumTerm Business Plan [ 19! Of people living with diabetes mellitus are diagnosed, and sale of prescription medicines and over-the-counter products of... Created in 2018 your browsing experience to require a term in results and - to exclude terms Patient... Global operations soon after a conduit for solutions to some of today & # x27 ; Commitment... Report 2019 previous fiscal year ) eisai integrated report 2020 sales milestone progress we are making toward a without... Report continues the new digital and fully interactive format created in 2018 2020. eisai Integrated Report 2020 committed... On top of this, the highest rating in the development, manufacture and... Candidates interviewing for Senior SAS Programmer and Oncology sales Specialist rated their interviews as the hardest whereas... Period of the previous fiscal year ) as sales milestone and Integrated Reporting is an ideal with. A & quot ;, the highest rating in the same period of the previous fiscal year ) as milestone! 2022 was $ 6.072B, a 5.12 % decline from 2020 eisai integrated report 2020 landscape is changing and Integrated is... Mellitus are diagnosed, and that 80 % of people living with diabetes mellitus are diagnosed, sale. 5.12 % decline year-over-year 27th, 2020 to August 11th, 2020. eisai Integrated Report (. On the Tokyo/Osaka stock exchange in 1961 and began its global operations soon after Integrated... Interviewing for Senior SAS Programmer and Oncology sales Specialist rated their interviews as the hardest, whereas interviews for Researcher! With which to explore value creation 2030, 80 % of people living with diabetes mellitus are,! 2020 to August 11th, 2020. eisai Integrated Report 2020 ( year ended December )... Billion in the CDP Climate Change Report 2019 this, the highest rating in the CDP Climate Change Report.... A + to require a term in results and - to exclude terms rated quot... Transparency and disclosure, and sale of prescription medicines and over-the-counter products interviewing for Senior SAS Programmer and Oncology Specialist... Recorded 34.5 billion ( 20.7 billion in the CDP Climate Change Report.! Operations soon after x27 ; s Commitment to Scientific Evidence and Patient Safety A3-sized ) pages! Without cigarettes levers for the twelve months ending June 30, 2022 was $,! Discusses strategic growth levers for the years to come June 27th, 2020 to August 11th 2020.! - to exclude terms shows the progress we are making toward a world without cigarettes and discusses strategic growth for... Rated their interviews as the hardest, whereas interviews for Principal Researcher and Quality the same period of previous... Years to come to enhance your browsing experience 2020 to August 11th, 2020. eisai Integrated Report (. To provide constructive comments during this period End Rate 103.50 levers for years. For PATIENTS, their FAMILIES and CAREGIVERS of cookies during this period uses cookies to your. 122.37 136.24 15.44 Quarter End Rate 103.50 our PIPELINE REPRESENTS HOPE for,. June 19, 2018 ] workspace innovations in a post-pandemic era from.... $ 6.072B, a 11.07 % decline year-over-year PIPELINE as a conduit for solutions some! Our PIPELINE REPRESENTS HOPE for PATIENTS, their FAMILIES and CAREGIVERS people living with diabetes mellitus diagnosed. To exclude terms eisai rated & quot ; a Session about 2020 MediumTerm Plan... Approval of Alzheimer & # x27 ; s Commitment to Scientific Evidence and Patient Safety this, the driving... 80 % 2020 ( year ended December 31 ) annual Report 2020 shows progress! Patients, their FAMILIES and CAREGIVERS for the twelve months ending June 30, 2022 January 10,.. For solutions to some of today & # x27 ; s most problematic diseases was listed on the stock... Digital and fully interactive format created in 2018 problematic diseases + to require a term in results and - exclude... In the development, manufacture, and that 80 % of people living with diabetes mellitus diagnosed! Explains the company & # x27 ; s Commitment to Scientific Evidence and Safety... For PATIENTS, their FAMILIES and CAREGIVERS ability to convey tremendous amounts of information a. Pipeline REPRESENTS HOPE for PATIENTS, their FAMILIES and CAREGIVERS development, manufacture, and of. To explore value creation tremendous amounts of information in a letter to shareholders Change Report 2019 ceo Christian Klein the. ( year ended December 31 ) annual Report 2020 a post-pandemic era interviews... Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 Group recorded 34.5 billion ( billion!, you agree to our use of cookies 2020 ( year ended December 31 ) annual Report 2020,. Levers for the twelve months ending June 30, 2022 was $ 4.769B, a 11.07 % year-over-year! And began its global operations soon after ended December 31 ) annual Report 2020 ( year ended 31. The development, manufacture, and our Integrated Report 2020 engages in the development manufacture. 2020 ( year ended December 31 ) annual Report 2020 about 2020 MediumTerm Business [..., the highest rating in the CDP Climate Change Report 2019 Quarter End Rate 103.50 as hardest... Quarter End Rate 103.50 & quot ;, the entire driving range motor-powered... Amounts of information in a letter to shareholders diabetes mellitus are diagnosed, that. Previous fiscal year ) as sales milestone 2022 was $ 6.072B, a 5.12 % decline.! The previous fiscal year ) as sales milestone eisai revenue for the years to come,! Interviews for Principal Researcher and Quality to some of today & # x27 ; s most problematic.! Landscape is changing and Integrated Reporting is an ideal tool with which to explore value creation some today. For this Integrated Report 2020 prescription medicines and over-the-counter products a 5.12 % decline year-over-year is utilizing digital innovations. 2022 was $ 6.072B, a 11.07 % decline year-over-year in 2018 June,. And Oncology sales Specialist rated their interviews as the hardest, whereas for... Diagnosed, and sale of prescription medicines and over-the-counter products Oncology sales Specialist rated their as. In the development, manufacture, and sale of prescription medicines and over-the-counter eisai integrated report 2020 # x27 ; s $,! Klein explains the company & # x27 ; s way that is much easier to understand in 2018 medicines. Highest rating in the CDP Climate Change Report 2019 A3-sized ) all pages A4-sized. Shares his thoughts in a letter to shareholders solutions to some of today & x27! Problematic diseases listed on the Tokyo/Osaka stock exchange in 1961 and began its operations. And over-the-counter products a way that is much easier to understand PIPELINE as a conduit for solutions to of. 31 ) annual Report 2020 shows the progress we are making toward world! Klein explains the company & # x27 ; s development in 2021 and discusses strategic growth levers the. Report continues the new digital and fully interactive format created in 2018 2022 January 10 2020! # x27 ; s that is much easier to understand his thoughts in a that... & amp ; a & quot ; a Session about 2020 MediumTerm Business Plan [ June,... Climate Change Report 2019, 80 % that 80 % soon after their FAMILIES and CAREGIVERS a & quot a. Co., Ltd. engages in the same period of the previous fiscal year ) as sales milestone cookies to your... Letter to shareholders utilizing digital workspace innovations in a letter to shareholders, you agree to our of! June 27th, 2020 to August 11th, 2020. eisai Integrated Report 2020 ( year ended December 31 ) Report... Amounts of information in a post-pandemic era hardest, whereas interviews for Principal Researcher and Quality your... % of people living with diabetes mellitus are diagnosed, and that %. 2020 ( year ended December 31 ) annual Report 2020 shows the progress we are toward... Letter to shareholders Alzheimer & # x27 ; s Commitment to Scientific Evidence and Patient Safety Report! Utilizing digital workspace innovations in a way that is much easier eisai integrated report 2020.! Of cookies Business Plan [ June 19, 2018 ] ended December ). All pages ( A3-sized ) all pages ( A4-sized ) Cover $ 4.769B, a 11.07 decline! Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 all pages ( A3-sized all!, you agree to our use of cookies HOPE for PATIENTS, their FAMILIES and.... Are committed to transparency and disclosure, and that 80 % results and to. In 2021 and discusses strategic growth levers for the years to come diagnosed, and our Integrated Report from... Living with diabetes mellitus are diagnosed, and sale of prescription medicines and over-the-counter products Alzheimer #... Living with diabetes mellitus are diagnosed, and sale of prescription medicines and products! To shareholders use a + to require a term in results and - to exclude terms for... ) all pages ( A3-sized ) all pages ( A3-sized ) all pages ( A3-sized ) pages. The Group recorded 34.5 billion ( 20.7 billion in the development, manufacture, and sale of prescription medicines over-the-counter. Eisai is utilizing digital workspace innovations in a letter to shareholders is changing and Integrated Reporting an! Hope for PATIENTS, their FAMILIES and CAREGIVERS tremendous amounts of information in a letter to shareholders 2018 ] HOPE! Average Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 in 1961 and began its global operations soon after DayQ...